|D003550||Cystic Fibrosis NIH||0.45|
There is one clinical trial.
The current project is based on the immunological studies covering the potential of disease induced immunoglobulins as treatment regime. We would be able to generate the concentrated antibodies specific against coronavirus (Covid-19). These antibodies can be used as serum therapy. Aside from a Covid-19 vaccine, antibodies from recovered patients could provide a short-term "passive immunization" to the disease. Those antibodies can be extracted from the blood serum of surviving patients and then injected into infected people. Passive immunization usually lasts for a few weeks or months, after which those borrowed or donated antibodies, get broken down by the host body within about 30 days. While drugs to treat patients with covid-19, and vaccines to prevent infection are being developed, a fast acting, stopgap serum therapy could be useful as a first aid for high-risk patients.
Description: total number of days the patient remain in hospitalMeasure: In hospital days Time: 14 days or discharge
Description: mortality if any in the study duration of 14 daysMeasure: 14 day mortality Time: 14 days
Description: reduction in D-dimers (< 250 ng/mL)Measure: D-dimers Time: 7 days
Description: reduction in C-Reactive protein (less than 10 mg/L)Measure: C-reactive protein Time: 7 days
Description: improvement in oxygen saturation (pulse oximeter readings within range of 95 to 100%)Measure: Oxygen saturation Time: 7 days
Description: reduction in TNF alpha after IVIG treatment (upto 8.1 pg/mL)Measure: TNF alpha Time: 7 days
Description: reduction in IL-6 after IVIG treatmentMeasure: IL-6 Time: 7 days
Description: reduction in ferritin levels after IVIG treatmentMeasure: Ferritin Time: 7 days
Description: safety and tolerabilityMeasure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports